Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs.
The remarkable progress made by molecular biology and molecular genetics during the past decade, and the advent of the novel tools of genomics and proteomics, are expected to reveal differential expression profiles of thousands of genes and proteins involved in the degeneration of dopamine-containing cells in Parkinson's disease and allow more focused treatments according to individual genotypes. Of particular interest is the application of microarrays in drug discovery and design to identify 'fingerprints' as potential candidate targets for drug intervention. The major microarray findings relevant to Parkinson's disease and its neurotoxin-induced animal and cell models will be discussed, with particular reference to the neuroprotective therapeutic potential that could arise from the development of drugs 'a la carte'.
Mandel
Silvia
S
Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Technion-Rappaport Faculty of Medicine, PO Box 9697, Haifa 31096, Israel.
Weinreb
Orly
O
Youdim
Moussa B H
MB
D000818:Animals; D004195:Disease Models, Animal; D015870:Gene Expression / Q000187:drug effects; D016678:Genome; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D020543:Proteome; D040901:Proteomics
D018696:Neuroprotective Agents; D020543:Proteome